PerkinElmer Inc. of Wellesley, Mass.,
and George Mason University of Fairfax, Va., have announced a five-year research
collaboration to develop approaches for cancer detection and risk stratification.
Scientists plan to design clinical assay platforms that use amino acid identification
of a protein fragment and its specific mass to identify biomarkers. The research
will use the company’s BioXpression platform and the university’s discovery
of an archive of protein fragments in human blood.
In other news, PerkinElmer has acquired
Agilix Corp.’s protein labeling technology. The labels use isobaric mass
tags to quantify expressed proteins from multiple samples. The company intends to
use the technology to increase the reach of quantitative proteomics to drug discovery
MORE FROM PHOTONICS MEDIA